Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Panbela Therapeutics Inc PBLA

Healthcare Biotechnology
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to... see more

Bullboard (OTCQB:PBLA)

View:
1 2 3 4 5 6 7 Next
Post by MikeTesteron Aug 02, 2024 11:30am

Panbela Therapeutics, Inc. (PBLA): Navigating the Challenges

https://beyondspx.com/2024/07/31/panbela-therapeutics-inc-pbla-navigating-the-challenges-of-advancing-innovative-therapeutics/
23
Comment by Iseneschalon Jan 29, 2024 8:46am

RE:PBLA ..... JUst remember what this game is all about!!!!

All I can say to all those that didn't listen is ....... I fore-warned you! Here is this a.m's NR...... Panbela Announces Pricing of Approximately $9.0 Million Public Offering 2024-01-29 ...more  
50
Discussion
Post by Iseneschalon Jan 26, 2024 3:58pm

PBLA .... I wish u all the best during AH

I don't trade After Hours Just remember that there will be a P.O announcement sooner than later and the share price will tank Cheers !
53
Post by Iseneschalon Jan 26, 2024 3:48pm

PBLA .... I am keeping all my profit

Not giving The Maggot squat ; ) Don't care where it goes to
67
Comment by Iseneschalon Jan 26, 2024 3:42pm

RE:PBLA ....And just for the record.....

Here we Go Packers ...Here We Go !!!!!
41
Discussion
Post by Iseneschalon Jan 26, 2024 2:38pm

PBLA ....And just for the record.....

I still think that this will get another run before the close. I'm not hanging around to see any carnage Just my humble opinion. Have a great weekend.......make sure you take a look at AVTX ;  ...more  
83
Discussion
Comment by Iseneschalon Jan 26, 2024 2:33pm

RE:PBLA...now wouldn't that be hilarious if this....

I am not greedy...........Scalped again As previously mentioned...I like to leave some profit for the next guy ; ) Thats enough for me....I'm going to let the dust settle....not going to swing ...more  
49
Discussion
Post by Iseneschalon Jan 26, 2024 2:11pm

PBLA...now wouldn't that be hilarious if this....

Tacked on another buck from here????
91
Discussion
Comment by Iseneschalon Jan 26, 2024 2:10pm

RE:RE:PBLA ....vols are minimal at best

How's it working out for everyone???? Time to like my prognostications??? Maybe
28
Discussion
1 2 3 4 5 6 7 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities